Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148059 | 0.82 | GRM5 (0.45) | GRM5CYP1A2CYP2C9CYP3A4KCNH2 | |
| SCHEMBL7907942 | 0.81 | HSD11B1 (0.45) | GRM5KCNH2 | |
| SCHEMBL7897358 | 0.81 | GRM5 (0.70) | GRM5CYP1A2CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1795107 | 0.80 | GRM5 (0.70) | GRM5NPC1RAB9AKMT2ASORT1 | |
| SCHEMBL1795941 | 0.79 | CYP3A4 (0.63) | GRM5NPC1RAB9AKMT2ASORT1 | |
| SCHEMBL1797017 | 0.77 | SORT1 (0.56) | GRM5NPC1RAB9AKMT2ASORT1 | |
| SCHEMBL1797770 | 0.77 | SORT1 (0.58) | GRM5NPC1RAB9AKMT2ASORT1 | |
| SCHEMBL15890663 | 0.76 | CYP1A2 (0.58) | GRM5CYP1A2CYP2C9CYP3A4KCNH2 | |
| SCHEMBL15890669 | 0.75 | CYP1A2 (0.76) | GRM5CYP1A2CYP2C9CYP3A4KCNH2 | |
| SCHEMBL15443995 | 0.74 | BRD4 (0.54) | GRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | GRM5 6/4885NPC1 4161/4885RAB9A 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.